JP2018522049A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522049A5
JP2018522049A5 JP2018505714A JP2018505714A JP2018522049A5 JP 2018522049 A5 JP2018522049 A5 JP 2018522049A5 JP 2018505714 A JP2018505714 A JP 2018505714A JP 2018505714 A JP2018505714 A JP 2018505714A JP 2018522049 A5 JP2018522049 A5 JP 2018522049A5
Authority
JP
Japan
Prior art keywords
hydrate
pharmaceutically acceptable
acceptable salt
formula
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018505714A
Other languages
English (en)
Japanese (ja)
Other versions
JP6815383B2 (ja
JP2018522049A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/043676 external-priority patent/WO2017023584A1/en
Publication of JP2018522049A publication Critical patent/JP2018522049A/ja
Publication of JP2018522049A5 publication Critical patent/JP2018522049A5/ja
Application granted granted Critical
Publication of JP6815383B2 publication Critical patent/JP6815383B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018505714A 2015-08-03 2016-07-22 がん処置のための組み合わせ療法 Expired - Fee Related JP6815383B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562200545P 2015-08-03 2015-08-03
US201562200549P 2015-08-03 2015-08-03
US201562200556P 2015-08-03 2015-08-03
US62/200,549 2015-08-03
US62/200,545 2015-08-03
US62/200,556 2015-08-03
US201562201009P 2015-08-04 2015-08-04
US62/201,009 2015-08-04
US201562235102P 2015-09-30 2015-09-30
US62/235,102 2015-09-30
PCT/US2016/043676 WO2017023584A1 (en) 2015-08-03 2016-07-22 Combination therapies for treating cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020171578A Division JP2021001237A (ja) 2015-08-03 2020-10-09 がん処置のための組み合わせ療法

Publications (3)

Publication Number Publication Date
JP2018522049A JP2018522049A (ja) 2018-08-09
JP2018522049A5 true JP2018522049A5 (enExample) 2019-09-05
JP6815383B2 JP6815383B2 (ja) 2021-01-20

Family

ID=56555867

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018505714A Expired - Fee Related JP6815383B2 (ja) 2015-08-03 2016-07-22 がん処置のための組み合わせ療法
JP2020171578A Pending JP2021001237A (ja) 2015-08-03 2020-10-09 がん処置のための組み合わせ療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020171578A Pending JP2021001237A (ja) 2015-08-03 2020-10-09 がん処置のための組み合わせ療法

Country Status (8)

Country Link
US (1) US20180207164A1 (enExample)
EP (1) EP3331531A1 (enExample)
JP (2) JP6815383B2 (enExample)
AU (1) AU2016304172A1 (enExample)
CA (1) CA2994265A1 (enExample)
HK (1) HK1255939A1 (enExample)
TW (1) TW201717953A (enExample)
WO (1) WO2017023584A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114522167A (zh) * 2018-07-31 2022-05-24 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
CA3133376A1 (en) * 2018-11-30 2020-06-04 Aptose Biosciences Inc. Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations
WO2021157650A1 (ja) * 2020-02-05 2021-08-12 カルナバイオサイエンス株式会社 抗がん剤組成物
WO2024037910A1 (en) * 2022-08-17 2024-02-22 Institut National de la Santé et de la Recherche Médicale Syk inhibitors for use in the treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104768581A (zh) * 2012-09-07 2015-07-08 吉宁特有限公司 II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗
CN111317821A (zh) * 2013-04-08 2020-06-23 药品循环有限责任公司 依鲁替尼联合疗法
AU2014273946B2 (en) * 2013-05-30 2020-03-12 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
MY178726A (en) * 2013-11-07 2020-10-20 Hoffmann La Roche Combination therapy of an afucosylated cd20 antibody with a btk inhibitor
UY35898A (es) * 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.
PT3179992T (pt) * 2014-08-11 2022-07-12 Acerta Pharma Bv Combinações terapêuticas de um inibidor de btk, um inibidor de pd-1 e/ou um inibidor de pd-l1
WO2016024230A1 (en) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, and/or a bcl-2 inhibitor
WO2016209961A1 (en) * 2015-06-23 2016-12-29 Gilead Sciences, Inc. Combination therapies for treating b-cell malignancies

Similar Documents

Publication Publication Date Title
JPWO2022014639A5 (enExample)
JP2024133474A5 (enExample)
JP2019501133A5 (enExample)
JP2014517050A5 (enExample)
JP2015535247A5 (enExample)
FI3157527T3 (fi) Ezh2-inhibiittoreita lymfoman hoitoon
JP2014513136A5 (enExample)
JP2015528471A5 (enExample)
KR102634247B1 (ko) 다발성 골수종을 치료하기 위한 약물 병용물
RU2018110647A (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
JP2014505735A5 (enExample)
CN105120868A (zh) 组合治疗
JP2016536286A5 (enExample)
JP2008521928A5 (enExample)
JP2012530779A5 (enExample)
JP2013507415A5 (enExample)
JP2014500295A5 (enExample)
JP2015524472A5 (enExample)
JP2016534063A5 (enExample)
JP2017529382A5 (enExample)
JP2017526677A5 (enExample)
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
JP2014525454A5 (enExample)
JP2014505107A5 (enExample)
JP2018522049A5 (enExample)